Eugenia Vispo
Overview
Explore the profile of Eugenia Vispo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaparro M, Baston-Rey I, Fernandez Salgado E, Gonzalez Garcia J, Ramos L, Palomares M, et al.
J Clin Med
. 2022 Aug;
11(15).
PMID: 35956133
Ustekinumab has shown efficacy in Crohn's Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the...
2.
Chaparro M, Baston-Rey I, Fernandez-Salgado E, Gonzalez Garcia J, Ramos L, Palomares M, et al.
Inflamm Bowel Dis
. 2022 Feb;
28(11):1725-1736.
PMID: 35166347
Background: Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn's disease (CD) patients in real-world clinical practice. Methods: A retrospective, multicentre...
3.
Wu J, Saksena M, Soriano V, Vispo E, Saksena N
Virol J
. 2015 Jan;
12:4.
PMID: 25623235
Background: Despite the easy accessibility and diagnostic utility of PBMCs and their potential to show distinct expression patterns associated with the accelerated disease progression in HIV/HCV co-infection, there has not...
4.
Feijoo M, Toro R, Lopez Vazquez de la Torre M, Lennie V, Arce C, Moreno V, et al.
AIDS
. 2014 Dec;
28(18):2693-9.
PMID: 25493595
Objective: Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with average survival of less than 3 years if left untreated. It is most common in patients infected with HIV....
5.
Soriano V, Vispo E, Sierra-Enguita R, de Mendoza C, Fernandez-Montero J, Labarga P, et al.
AIDS
. 2014 Aug;
28(16):2389-94.
PMID: 25111082
Background: Hepatitis delta virus (HDV) produces the most severe form of chronic viral hepatitis. We explored whether prolonged tenofovir exposure might be beneficial on hepatitis delta in HIV-infected patients. Methods:...
6.
Vispo E, Barreiro P, Plaza Z, Fernandez-Montero J, Labarga P, de Mendoza C, et al.
AIDS
. 2014 Mar;
28(10):1473-8.
PMID: 24637541
Background: A quarter of individuals acutely infected with hepatitis C virus (HCV) clear the virus spontaneously. Once chronic infection is established, HCV elimination generally can only be achieved using specific...
7.
Fernandez-Montero J, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al.
Clin Infect Dis
. 2014 Mar;
58(11):1549-53.
PMID: 24633686
Background: Coinfection with hepatitis viruses is common in individuals infected with human immunodeficiency virus (HIV) and has become a leading cause of complications and death in those receiving antiretroviral therapy...
8.
Barreiro P, Vispo E, Maida I, Aguilera A, Fernandez-Montero J, de Mendoza C, et al.
Antivir Ther
. 2014 Feb;
19(7):723-4.
PMID: 24535551
No abstract available.
9.
Fernandez-Montero J, Vispo E, Soriano V
Expert Opin Pharmacother
. 2013 Dec;
15(2):211-9.
PMID: 24289800
Introduction: The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including...
10.
Fernandez-Montero J, Barreiro P, Vispo E, Labarga P, Sanchez-Parra C, de Mendoza C, et al.
Antivir Ther
. 2013 Nov;
19(3):287-92.
PMID: 24192598
Background: Advanced liver fibrosis frequently develops in patients with chronic hepatitis C coinfected with HIV. Non-invasive techniques for staging liver fibrosis, such as transient elastometry, may allow both periodic monitoring...